Which is the better health care breaker?

Progeny or hymns and hers?

Welcome to Motley Full Money.

Good morning. I am your host, Tim Byers. With me are two of my favorite fools, San Mateo, and Alicia Alfieri from the Rule Breakers team.

We're going to do a small debate here. And the way this is going to work, Fools, is that I am going to ask you to make your case

first for Progeny, then for Hems and Hers. I'm going to ask you a follow-up question, each of you,

and then I'm going to make a call on which one is going on my watch list. So the audience is your audience, but also I am your audience. So you got to

convince me. So Alicia, make the case. Why do I want to be invested in progeny? Okay. So progeny is

essentially a health benefit that employers provide as part of their overall benefits package.

Think of it like a super customer-focused health benefit, including drug coverage for fertility

and family building. So infertility is a migraine-level problem that roughly one in six

people of reproductive age experience, it's also an expensive problem. So depending

on where you live, a single round of IVF can cost $10,000 to $20,000 or more, and that might not even

include medication. Prior to companies like progeny, if fertility services were covered by

insurance, it could be restrictive with lifetime dollar maximums and

things like mandated step therapy, which was expensive, wasted time, and wasn't a personalized

approach. So of the six signs of the rule breaker, progeny has about, we'll say three and a half.

The most important part, I think, is their sustainable advantage.

They have a strong brand power and an excellent network with great clinical outcomes.

They have a strong brand in the core market.

They're expanding into services like pregnancy support and menopause care.

It also has an impressive network of fertility specialists across the U.S. that really deliver impressive results by harnessing expertise and data. So, for example,

...